The most common adverse reactions reported in clinical trials were injection site reactions (erythema, pruritus, pain) occurring in approximately 8-13% of patients
Therefore, the design, discovery, and development of short and long-acting peptide-based GLP-1RAs, including small-molecule agonists are desirable for therapeutic applications beyond T2DM
GLP-1s provide cardiovascular benefits beyond glycemic control, such as lowering blood pressure, improving endothelial function, and reducing markers of inflammation
These Are My Go-To Simple Meals Why Im Choosing Not to Take GLP-1s, Even Though Everyone Expects Me To Get more of SELFs great service journalism delivered right to your inbox.
As a JAMA Dermatology editorial board member, I'm proud the journal is investing in this evidence base